Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Addressing cardiotoxicity concerns with the use of gilteritinib

Eunice Wang • 12 Dec 2022
ASH 2022
Acute Myeloid Leukemia Leukemia Dasatinib Gilteritinib Imatinib Nilotinib

Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, comments on the importance of managing the potential cardiotoxicity associated with the use of gilteritinib when treating patients with acute myeloid leukemia (AML). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eunice Wang

2:49
Results of a Phase I trial investigating CYNK-001, a placental NK-cell product, in patients with AML
Eunice Wang • 10 Dec 2023
1:30
A Phase I trial investigating a novel oral FLT3 inhibitor, BMF-500, in FLT3-mutant AML
Eunice Wang • 10 Dec 2023
3:03
The effect of BMI on survival outcomes in adolescents and young adults with AML
Eunice Wang • 10 Dec 2023
Novel targets, combinations & treatments
Eunice Wang et al. • 4 Sep 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals